Table 3.
Summary of Pre- and Post-vaccination Antibody Titers and Fold Rises in Each Vaccination Group
| Assay | Strain | Vaccination Group | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Standard-dose QIV, n = 200 | MF59-adjuvanted TIV, n = 200 | High-dose TIV, n = 200 | Recombinant-HA QIV, n = 200 | ||||||
| Estimate | (95% CI) | Estimate | (95% CI) | Estimate | (95% CI) | Estimate | (95% CI) | ||
| HAI | A/Michigan/45/2015 (H1N1) | ||||||||
| Day 0 GMT | 17 | (14–20) | 17 | (15–20) | 20 | (17–24) | 16 | (14–19) | |
| Day 30 GMT | 69 | (58–83) | 94* | (78–114) | 125* | (102–152) | 85 | (69–105) | |
| Mean fold rise from D0 to D30 | 4.1 | (3.5–4.9) | 5.5* | (4.6–6.6) | 6.1* | (5.1–7.3) | 5.3* | (4.4–6.3) | |
| % with ≥4-fold rise from D0 to D30b | 42% | (36–50%) | 60%* | (53–67%) | 59%* | (52–66%) | 60%* | (53–67%) | |
| HAI | A/Hong Kong/4801/2014 (H3N2) egg-like | ||||||||
| Day 0 GMT | 46 | (39–56) | 49 | (41–59) | 45 | (38–54) | 54 | (45–64) | |
| Day 30 GMT | 158 | (135–186) | 207* | (178–241) | 214* | (183–250) | 254* | (218–295) | |
| Mean fold rise from D0 to D30 | 3.4 | (2.8–4.1) | 4.2* | (3.5–5.1) | 4.7* | (3.9–5.7) | 4.7* | (3.9–5.7) | |
| % with ≥4-fold rise from D0 to D30a | 41% | (34–48%) | 48% | (40–55%) | 54%* | (46–61%) | 56%* | (48–63%) | |
| MN | A/Hong Kong/4801/2014 (H3N2) cell-like | ||||||||
| Day 0 GMT | 38 | (31–46) | 43 | (35–53) | 34 | (28–41) | 48 | (39–59) | |
| Day 30 GMT | 87 | (72–106) | 125* | (102–152) | 116* | (95–141) | 223* | (189–263) | |
| Mean fold rise from D0 to D30 | 2.3 | (2.0–2.6) | 2.9* | (2.5–3.4) | 3.4* | (2.9–4.0) | 4.7* | (3.9–5.6) | |
| % with ≥4-fold rise from D0 to D30a | 28% | (22–35%) | 39%* | (32–46%) | 47%* | (40–54%) | 57%* | (50–64%) | |
| HAI | B/Brisbane/60/2008 (Victoria lineage) | ||||||||
| Day 0 GMT | 24 | (20–28) | 31* | (26–38) | 31* | (26–37) | 29* | (25–35) | |
| Day 30 GMT | 89 | (75–105) | 95 | (81–112) | 132* | (112–157) | 90 | (76–107) | |
| Mean fold rise from D0 to D30 | 3.7 | (3.2–4.4) | 3.0 | (2.6–3.5) | 4.2 | (3.5–5.0) | 3.1 | (2.7–3.5) | |
| % with ≥4-fold rise from D0 to D30a | 48% | (41–56%) | 44% | (37–51%) | 52% | (45–60%) | 44% | (37–51%) | |
| HAI | B/Phuket/3073/2013b (Yamagata lineage) | ||||||||
| Day 0 GMT | 37 | (31–44) | 41 | (35–49) | 41 | (34–50) | 45 | (38–54) | |
| Day 30 GMT | 121 | (104–141) | 63* | (54–74) | 68* | (57–81) | 131 | (111–155) | |
| Mean fold rise from D0 to D30 | 3.3 | (2.8–3.8) | 1.5* | (1.4–1.7) | 1.6* | (1.5–1.8) | 2.9 | (2.5–3.3) | |
| % with ≥4-fold rise from D0 to D30a | 42% | (36–50%) | 12%* | (8–18%) | 15%* | (10–21%) | 42% | (36–50%) | |
*
Values that are significantly different from the corresponding value in the standard-dose group. Statistical significance was designated at P value <.05.
Abbreviations: CI, confidence interval; D, day; GMT, geometric mean titer; HA, hemagglutinin; HAI, hemagglutination inhibition assay; MN, microneutralization assay; QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.
a
At least a 4-fold rise from D0 to D30 with D30 titer ≥40.
b
Note that a B/Yamagata lineage virus was not included in the MF59-adjuvanted TIV and the high-dose TIV.